Breast cancer is a heterogeneous group of diseases survival from which depends on stage at diagnosis. The development of blood-based biomarkers which may facilitate earlier detection and possibly subtype delineation remains ...

microRNAs (miRNA) have been highlighted as potential circulating biomarkers and as therapeutic targets for breast cancer. Recent evidence suggests that miRNAs are transported in protective microvesicles called exosomes, ...

Breast cancer is the most frequently diagnosed female malignancy worldwide, causing the majority of cancer-related deaths amongst women. While the management of this disease has transformed dramatically in recent years, ...

It has, for many years, been acknowledged that “breast cancer” is an umbrella term for many genetically and immunophenotypically distinct malignancies of the breast. Treatment paradigms are shifting in direct response to ...

Complete surgical resection with disease free margins remains the cornerstone of effective breast cancer treatment. Breast cancer management continues to evolve with the development of more sophisticated techniques of ...

Introduction About 30% of breast cancers are HER2 receptor positive, these breast cancers traditionally had a poor prognosis but the introduction of targeted anti-HER2 therapy (Trastuzumab) has resulted in a vast improvement ...

MicroRNAs play a critical role in regulation of gene expression and are known to be dysregulated in breast cancer. The aim of this study was investigate four microRNAs miR-875-5p, miR-339-5p, miR-10a and miR-379 which were ...

Identification of biomarkers has proven valuable in prognostication and treatment stratification of individual cases of breast cancer. microRNAs, short non-coding RNA molecules which negatively regulate translation of mRNA, ...

Breast cancer is the most common female malignancy worldwide, and the second most common cause of cancer-related deaths in women. Twin studies estimate that up to one third of breast cancers are the result of hereditary ...

Stressful conditions of the tumour microenvironment which overwhelm the folding capacity of the endoplasmic reticulum (EnR) activate an evolutionary conserved signalling pathway known as the unfolded protein response (UPR). ...